Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML
A Phase 1 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of LAVA-051 in Patients with Relapsed or Refractory CLL, MM, or AML
Sponsor: Lava Therapeutics
Terminated
The decision to discontinue LAVA-051clinical trial follows a recent review of the competitive landscape that has continued to evolve (Business decision). The decision is not due to safety concerns.
Other terminated trials from Lava Therapeutics
More terminations from Lava Therapeutics
A PHASE1 clinical study on Acute Myeloid Leukemia and Chronic Lymphocytic Leukemia, this trial is terminated or withdrawn. The trial is conducted by Lava Therapeutics and has accumulated 12 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Feb 2025 — Present [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated · Phase: PHASE1/PHASE2 → PHASE1
-
Sep 2024 — Feb 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jul 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2023 — Jul 2023 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 7 earlier versions
-
May 2023 — Jun 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2023 — May 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2023 — Apr 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2022 — Feb 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2021 — Sep 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Lava Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .